Prescribing Information
Important Safety Information
For Patients

SCIENTIFIC EVIDENCE*

Greater Lubrication and Superior Friction Reduction3*

HYMOVIS® ONE is a true viscoelastic hydrogel - its unique molecular structure significantly improved lubrication, reducing friction on cartilage in a preclinical analysis3*
HA effects of friction reduction on cartilage at various sliding speeds*

Sliding Speed (mm/s)

*Preclinical test data may not be indicative of human clinical outcomes.
Several hyaluronan (HA) viscosupplement products were assessed in this preclinical analysis. This graph demonstrates preclinical comparison of selected single-injection HA viscosupplements.
The molecule of HYMOVIS® is the same as HYMOVIS® ONE. The molecule of Synvisc® is the same as Synvisc® One. Third-party trademarks used herein are trademarks of their respective owners PBS = Phosphate buffered saline

In a pre-clinical study

HYMOVIS® ONE demonstrated greater recovery of molecular structure (elasticity) under repeated mechanical stress4*

Comparison with chemically cross-linked high molecular weight HA viscosupplements4

All 3 HAs started at a pre-stress baseline of 100% and had an instantaneous post-stress response of 29%.*

Following repeated stress, the structure of HYMOVIS® stabilizes due to the reversible hydrophobic interactions of the amide-containing alkyl side chains.*
Study design: Recovery of mechanical properties after a shock was investigated as a function of time by oscillatory measurement after destruction of the gel network for each product: HYMOVIS®, Synvisc®, and Durolane®. The stress cycle was repeated 6 times.
*Preclinical test data may not be indicative of human clinical outcomes.
The molecule of HYMOVIS® is the same as HYMOVIS® ONE. The molecule of Synvisc® is the same as Synvisc® One.
Third-party trademarks used herein are trademarks of their respective owners.

Indication

HYMOVIS® ONE is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy or simple analgesics (e.g., acetaminophen).

Important Safety Information

HYMOVIS® ONE is contraindicated in patients with known hypersensitivity (allergy) to hyaluronate preparations or gram-positive bacterial proteins. Do not administer
HYMOVIS® ONE to patients with infections or skin diseases in the area of the injection site or joint. The safety and effectiveness of HYMOVIS® ONE has not been established in pregnant women, nursing mothers, or children or for the use of in joints other than the knee, or concomitant use with other intra-articular (IA) injections. The effectiveness of repeat treatment cycles of HYMOVIS® ONE has not been established. No serious adverse events or pseudoseptic reactions were reported in the HYMOVIS® ONE clinical study. The adverse events experienced and reported in the HYMOVIS® ONE clinical study were joint swelling, metatarsalgia, neck pain and headache.

Rx Only. See package insert for full prescribing information including indications, contraindications, adverse events, warnings, precautions, and side effects.

About
Hymovis® One

Click here

CLINICAL SAFETY AND
EFFICACY

Click here

HOW TO ORDER

Click here

PROVIDER
REIMBURSEMENT 

AND SUPPORT

Click here

Patients Resources

Click here

References
3. Bonnevie ED, Galesso D, Secchieri C, Bonassar LJ (2019) Frictional characterization of injectable hyaluronic acids is more predictive of clinic outcomes than traditional rheological or viscoelastic characterization. PLoS ONE 14(5): e0216702. https://doi.org/10.1371/journal.pone.0216702
4. Finelli I, Chiessi E, Galesso D, Renier D, Paradossi G. A new viscosupplement based on partially hydrophobic hyaluronic acid: a comparative study. Biorheology. 2011;48(5):263-275